Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

BACKGROUND: To evaluate patient-reported outcomes with ramucirumab plus docetaxel, a regimen which improved progression-free survival in platinum-refractory advanced urothelial carcinoma (aUC). METHODS: RANGE—a randomized, double-blinded, phase 3 trial in patients with platinum-refractory aUC. Ramuc...

Descripción completa

Detalles Bibliográficos
Autores principales: Necchi, Andrea, Nishiyama, Hiroyuki, Matsubara, Nobuaki, Lee, Jae-Lyun, Petrylak, Daniel P., de Wit, Ronald, Drakaki, Alexandra, Liepa, Astra M., Mao, Huzhang, Bell-McGuinn, Katherine, Powles, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648381/
https://www.ncbi.nlm.nih.gov/pubmed/33160359
http://dx.doi.org/10.1186/s12894-020-00752-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648381/
https://www.ncbi.nlm.nih.gov/pubmed/33160359
http://dx.doi.org/10.1186/s12894-020-00752-w

Ejemplares similares